10588611 - GAU: 1625

BN/SB/08A/B

Substitute for form 1449A/PTO				Complete if Known		
				I.A. Number	PCT/JP2005/001764	
INFO	RMATION D	ISC	CLOSURE	I.A. Filing Date	February 7, 2005	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Kazuo HATTORI	
• • • • • • • • • • • • • • • • • • • •				Group Art Unit	Not Yet Known	
(use as many sheets as necessary)				Examiner Name	Not Yet Known	
Sheet	1	of	2	Attorney Docket Number	HATTORI=3	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (II} known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA	US-4,942,163	07-17-1990	Carl H. BEHRENS		
		US-				
		US-				
		US-				
		US-				

	FORE	IGN PATENT D	CUMENTS		
Cite No.1	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
AB	WO 99/11624 A1	03-11-1999	GUILFORD PHARMACEUTICALS		
AC	WO 98/51307	11-19-1998	OCTAMER, INC.		
	No. ¹	Foreign Patent Number Cite No.1 (known) AB WO 99/11624 A1	Foreign Patent Number Cite No.1 Country Code ³ Number ⁴ Kind Code ⁵ (if MM-DD-YYYY AB WO 99/11624 A1 03-11-1999	Cite No.1 Country Code ³ Number ⁴ Kind Code ⁵ (if MM-DD-YYYY Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant of Cited Document Name of Patentee or Applicant Name or Applicant Name of Patentee or Applicant Name or Applicant Na	Foreign Patent Number Cite No. 1 AB WO 99/11624 A1 Foreign Patent Number Publication Date MM-DD-YYYY Publication Date MM-DD-YYYY Publication Date MM-DD-YYYY Publication Date MM-DD-YYYY Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear Guil-FORD PHARMACEUTICALS

		NON PATENT LITERATURE DOCUMEN	TS / OTHER INF	ORMATION		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title magazine, journal, serial, symposium, catalog, etc.), date, page(s), publishe	volume-issue number		T ²	
	AD	Noboru YAGI et al., "Syntheses of N-Substituted-7-acylamir 1-a]-isoquinoline Derivatives and their Fluorescence Spectro 1969.			Abs.	
	AE	Won-Jea CHO et al., "Synthesis And Biological Evaluation of Bioorganic & Medical Chemistry Letters, Vol. 8, pp. 41-46, 1		es As Antitumor Agents",		
	AF	Alain ROSE et al., "Oxygen Heterocycles. Part XIII. ¹ From benzodiazepines", <u>J. Chem. Soc.</u> , (C), 1968, pp. 2205-2208		and 4-Aryl-5 <i>H</i> -2,3-		
	AG	Graham S. POINDEXTER, "Convenient Preparation of 3-St 47, pp. 3787-3788, 1982.	bstituted 1(2H)-lso	quinolinones", <u>J. Org. Chem.,</u> Vol.		
	АН	Won-Jea CHO et al., "Synthesis and Antitumor Activity of 3- 20, No. 3, pp. 264-268, 1997.	Arylisoquinoline De	erivatives", Arch. Pharm. Res., Vol.		
	Al	Seung Hoon CHEON et al., "Structure-Activity Relationship Arch. Pharm. Res., Vol. 24, No. 4, pp. 276-280, 2001.	Studies of Isoquino	olinone Type Anticancer Agent",		
	AJ	Won-Jea CHO et al., "Molecular Modeling of 3-Arylisoquino Comparative Molecular Field Analysis Study", <u>Bioorganic &</u> 2002.				
Examir Signati		/Zinna Davis/ (10/01/2009) Date Considered				

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached EFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/

Receipt date: 10/10/2006

10588611 - GAU: 1625

BN/SB/08A/B

Substitute for form 1449A/PTO				Complete if Known		
00000.0				I.A. Number	PCT/JP2005/001764	
INFO	RMATION D	ISC	CLOSURE	I.A. Filing Date	February 7, 2005	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Kazuo HATTORI	
				Group Art Unit	Not Yet Known	
	(use as many sheets	s <i>as</i> n	ecessary)	Examiner Name	Not Yet Known	
Sheet	2	of	2	Attorney Docket Number	HATTORI=3	

he item (book, city and/or country where and oxysanguinarine 2766, 2004. erberine Alkaloids 2, 2004. ation of Aryl	T²
erberine Alkaloids '2, 2004. ation of Aryl	
2, 2004. ation of Aryl	
-	
yzed Synthesis of Aryl	
Halides", <u>Organic</u>	
molecular Aryl	-
lides and the N-	
lides", <u>J. Am. Chem.</u>	
ocycles, Vol. 29, No. 4,	
- a	Halides", <u>Organic</u> rmolecular Aryl alides and the <i>N</i> - alides", <u>J. Am. Chem.</u> and Related Salts and High Effective Flourine ocycles, Vol. 29, No. 4,

Examiner	/Zinna Davie/ /10/01/2000\	Date	
Signature	/Zinna Davis/ (10/01/2009)	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.